AR007609A1 - Una composicion farmaceutica - Google Patents

Una composicion farmaceutica

Info

Publication number
AR007609A1
AR007609A1 ARP970102687A ARP970102687A AR007609A1 AR 007609 A1 AR007609 A1 AR 007609A1 AR P970102687 A ARP970102687 A AR P970102687A AR P970102687 A ARP970102687 A AR P970102687A AR 007609 A1 AR007609 A1 AR 007609A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
ssri
composition
myrta
lithoxetine
Prior art date
Application number
ARP970102687A
Other languages
English (en)
Spanish (es)
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR007609(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon Nv filed Critical Organon Nv
Publication of AR007609A1 publication Critical patent/AR007609A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP970102687A 1996-06-19 1997-06-19 Una composicion farmaceutica AR007609A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (1)

Publication Number Publication Date
AR007609A1 true AR007609A1 (es) 1999-11-10

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102687A AR007609A1 (es) 1996-06-19 1997-06-19 Una composicion farmaceutica

Country Status (24)

Country Link
US (1) US5977099A (fr)
JP (2) JP4925074B2 (fr)
KR (1) KR100481254B1 (fr)
CN (1) CN1132581C (fr)
AR (1) AR007609A1 (fr)
AT (1) ATE213159T1 (fr)
AU (1) AU727851B2 (fr)
BR (1) BR9703624A (fr)
CA (1) CA2208199C (fr)
CZ (1) CZ290691B6 (fr)
DE (1) DE69710390T2 (fr)
DK (1) DK0813873T3 (fr)
ES (1) ES2172744T3 (fr)
HU (1) HU225534B1 (fr)
ID (1) ID17051A (fr)
IL (1) IL121076A (fr)
NO (1) NO313177B1 (fr)
NZ (1) NZ328113A (fr)
PL (1) PL188520B1 (fr)
PT (1) PT813873E (fr)
RU (1) RU2181287C2 (fr)
SG (1) SG60073A1 (fr)
TR (1) TR199700522A2 (fr)
ZA (1) ZA975335B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
DK1030667T3 (da) * 1997-11-14 2005-06-20 Akzo Nobel Nv Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
CA2396066A1 (fr) * 2000-01-19 2001-07-26 Akzo Nobel N.V. Association de medicaments pour le traitement de depressions et de troubles s'y rapportant, comprenant de la mirtazapine
IL150290A0 (en) * 2000-02-11 2002-12-01 Akzo Nobel Nv The use of mirtazapine for the treatment of sleep disorders
WO2002036113A1 (fr) * 2000-11-01 2002-05-10 Respiratorius Ab Composition comprenant des agonistes (5ht-4) et des antagonistes (5ht-2, 5ht-3) recepteurs de la serotonine
WO2002064735A2 (fr) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methodes permettant d'ameliorer le traitement de depressions graves par genotypage visant a determiner le gene associe a l'apolipoproteine e4 et d'ameliorer la reponse therapeutique de personnes souffrant de depression grave et porteuses du gene associe a l'apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
BR0308556A (pt) * 2002-03-21 2005-05-03 Martin C Hinnz Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas
PL376832A1 (pl) * 2002-11-07 2006-01-09 Torrent Pharmaceuticals Ltd. Sposób wytwarzania polimorficznej postaci chlorowodorku sertraliny
NZ556779A (en) 2002-12-27 2008-12-24 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05008943A (es) * 2003-02-21 2005-11-08 C Hinz Martin Tecnologia de optimizacion del segmento de sistema de serotonina y catecolamina.
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004096201A1 (fr) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions influant sur la perte de poids
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1667972B1 (fr) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereoisomeres de 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
RU2283097C2 (ru) * 2004-11-16 2006-09-10 Эльвира Ивановна Белобородова Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
EP1827450A4 (fr) * 2004-11-17 2009-04-22 Cypress Bioscience Inc Methodes servant a limiter les effets secondaires d'un traitement par mirtazapine
CN101060860B (zh) * 2004-11-19 2013-07-17 Msd欧斯股份有限公司 用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
EP2167096A4 (fr) * 2007-06-13 2010-07-14 Cypress Bioscience Inc Amélioration de la tolérance à la mirtazapine et à un second principe actif par utilisation combinée de ces derniers
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
WO2009158114A1 (fr) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Procédés pour traiter des pathologies des graisses viscérales
US8768578B2 (en) 2009-06-09 2014-07-01 Sumitomo Heavy Industries, Ltd. Hybrid excavator and method of controlling hybrid excavator
WO2011059207A2 (fr) * 2009-11-13 2011-05-19 Green Cross Corporation Dérivés de purine contenant une arylpipérazine et leurs applications
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
DK0431663T3 (da) * 1989-12-06 1994-03-07 Akzo Nobel Nv Stabiliserende opløsninger af psykotrope midler
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
ATE232384T1 (de) * 1997-10-03 2003-02-15 Cary Medical Corp Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion

Also Published As

Publication number Publication date
PT813873E (pt) 2002-06-28
KR980000447A (ko) 1998-03-30
HUP9701068A3 (en) 2000-07-28
SG60073A1 (en) 1999-02-22
KR100481254B1 (ko) 2005-09-12
DE69710390D1 (de) 2002-03-21
NO972816L (no) 1997-12-22
TR199700522A3 (tr) 1998-01-21
ID17051A (id) 1997-12-04
US5977099A (en) 1999-11-02
HK1006081A1 (en) 1999-02-12
JP2009137970A (ja) 2009-06-25
HUP9701068A2 (hu) 1998-08-28
NO313177B1 (no) 2002-08-26
CZ290691B6 (cs) 2002-09-11
DE69710390T2 (de) 2002-08-14
CZ187097A3 (cs) 1998-01-14
JP4925074B2 (ja) 2012-04-25
JPH1067663A (ja) 1998-03-10
CN1132581C (zh) 2003-12-31
ZA975335B (en) 1998-01-26
BR9703624A (pt) 1998-09-01
NZ328113A (en) 1999-09-29
PL320628A1 (en) 1997-12-22
HU9701068D0 (en) 1997-08-28
AU2612997A (en) 1998-01-08
ATE213159T1 (de) 2002-02-15
PL188520B1 (pl) 2005-02-28
CA2208199A1 (fr) 1997-12-19
NO972816D0 (no) 1997-06-18
AU727851B2 (en) 2001-01-04
IL121076A (en) 2000-10-31
TR199700522A2 (xx) 1998-01-21
RU2181287C2 (ru) 2002-04-20
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
MX9704579A (es) 1998-07-31
DK0813873T3 (da) 2002-05-27
ES2172744T3 (es) 2002-10-01
CN1173330A (zh) 1998-02-18
CA2208199C (fr) 2006-10-24

Similar Documents

Publication Publication Date Title
ES2172744T3 (es) Composiciones farmaceuticas que comprenden mirtazapina y uno o varios inhibidores selectivos de asimilacion de serotonina.
EA200100022A1 (ru) Композиции с контролируемым высвобождением пароксетина
BR0112540A (pt) Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c
CO4900058A1 (es) Terapia de combinacion para el tratamiento de psicosis
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
CO5251409A1 (es) Combinacion de un inhibidor de la recaptacion de seretonina e irandalona
UY28041A1 (es) Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial.
ES2188177T3 (es) Composicion para la prevencion y/o el tratamiento de la osteoporosis y las alteraciones debidas al sindrome menopausico, que comprende propionil-l-carnitina y genisteina.
MY134110A (en) Combinations of reboxetine and neuroleptic agents
JPH1067663A5 (fr)
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
DE60026146D1 (de) Verwendung von dapoxetin, a selektiver serotonin-aufnahme inhibitor mit schnellem wirkungseintritt, zur behandlung von sexueller dysfunction
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
AR042039A1 (es) Isomeros posicionales del ifn peg alfa 2 a
BR0012951A (pt) Agonistas de retinóides seletivos
PY0106515A (es) Compuestos de eter difenilico utiles en terapia
MX9706957A (es) Composicion que contiene amlodipina, o una sal, o felodipina y un inhibidor de enzima convertidora de angiotensina.
EP1254668A3 (fr) Combinaison d'un inhibiteur de la recapture de la sérotonine et d'un GABA-A alpha 2/3 agoniste pour l'utilisation dans l'anxiété et la dépression
ATE451934T1 (de) Pharmazeutische zusammensetzung zur behandlung von rhinitiden
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
BRPI0415187A (pt) composição, método para matar bactérias, e, usos de composição e de bacteriófago
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina
AR017884A1 (es) Proceso para preparar una composicion farmaceutica que comprende zafirlukast, dicha composicion farmaceutica y metodo para tratar pacientes usando lacomposicion

Legal Events

Date Code Title Description
FG Grant, registration